Lidoderm® Lidocaine Cataplasms was approved for marketing in China in 2024, and its use for postherpetic neuralgia (PHN) treatment has been supported by consensus in clinical practice guidelines both in China and abroad Leveraging the advantages of its original brand, the Product can form in-depth synergy with the Group’s existing products in terms of expert resources and marketing channels; meanwhile, the Group will actively develop diverse marketing models such as new retail, further accelerating the development of the out-of-hospital market China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 12 February 2026, the Group through subsidiaries of the Company entered into an exclusive distribution agreement (the “Agreement”) with Teikoku Pharma USA, Inc. (“TPU”, a subsidiary of Japan-based Teikoku Seiyaku Co., Ltd (“TSC”), collectively referred to as the “Cooperation Partner”) for Lidoderm® Lidocaine Cataplasms (the “Product”). In accordance with […]
Learn More
CMS-D017 is a novel selective small-molecule inhibitor of complement factor B（CFB）.By targeting and inhibiting CFB, it blocks abnormal activation of the alternative complement pathway, which reduces damage to target tissues and organs caused by the membrane attack complex, and effectively slows the progression of a range of complement dysregulation-related inflammatory responses and autoimmune diseases. CMS-D017 has demonstrated excellent efficacy and safety in preclinical studies. Besides paroxysmal nocturnal hemoglobinuria(which has been approved for drug clinical trials), it is also being developed for clinical use in the treatment of complement-mediated kidney diseases, including IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis, C3 glomerulopathy, etc.; providing a potentially better therapeutic alternative for patients. Upon approval for marketing, CMS-D017 will synergize with the marketed innovative drug Velphoro (hyperphosphatemia of Chronic Kidney Disease) and the new drug currently under NDA review, Desidustat Tablets(renal anemia), in expert networks and market resources, collectively elevating the Group’s capabilities in the field of nephrology. […]
Learn MoreCMS-D017 is a novel selective small-molecule inhibitor of complement factor B (CFB). By targeting and inhibiting CFB, it blocks abnormal activation of the alternative complement pathway, which reduces damage to target tissues and organs caused by the membrane attack complex, and effectively slows the progression of a range of complement dysregulation-related inflammatory responses and autoimmune diseases. CMS-D017 has demonstrated excellent efficacy and safety in preclinical studies and is being developed for clinical use in the treatment of paroxysmal nocturnal hemoglobinuria, providing a potentially better therapeutic alternative for patients. Upon approval for marketing, CMS-D017 will synergize with the marketed innovative drug Velphoro (hyperphosphatemia of Chronic Kidney Disease) and the new drug currently under NDA review, Oxemia (renal anemia), in expert networks and market resources, collectively elevating the Group’s capabilities in the field of nephrology. China Medical System Holdings Limited ( “CMS” or the “Group”) is pleased to announce that innovative drug CMS-D017 […]
Learn MoreThe news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.
